Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515073 · ClinicalTrials.gov registry record · Phase 2
Papillary Serous Carcinoma of the Endometrium
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00515073: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00515073 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00515073, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Primary Objectives: * To evaluate the results of Paclitaxel and pelvic radiation in pelvic confined papillary serous carcinoma of the endometrium for both local control and overall survival. * To evaluate the toxicity of Paclitaxel and pelvic radiation. * To collect and evaluate patients' quality of life/symptom assessment data.
Interventions
- DRUG Paclitaxel
- DRUG Dexamethasone
- DRUG Diphenhydramine
- DRUG Cimetidine
- RADIATION Pelvic Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-04 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515073
The ClinicalTrials.gov registry entry for NCT00515073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Paclitaxel is the first listed.
NCT00515073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00515073 about?
NCT00515073 is a clinical study titled "Papillary Serous Carcinoma of the Endometrium". Primary Objectives: * To evaluate the results of Paclitaxel and pelvic radiation in pelvic confined papillary serous carcinoma of the endometrium for both local control and overall survival. * To evaluate the toxicity of Paclitaxel and pelvic radiation. * To collect and evaluate patients' quality o...
What is the current status of trial NCT00515073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2001-04. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00515073?
The interventions under investigation include: Paclitaxel (DRUG), Dexamethasone (DRUG), Diphenhydramine (DRUG), Cimetidine (DRUG), Pelvic Radiation (RADIATION).
Who is sponsoring clinical trial NCT00515073?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.